ConVerd's First Oncolytic Vaccinia Virus Product hV01 Completes First Patient Dosing in Clinical Trial

On July 14, 2023, The Phase I clinical study of hV01, ConVerd's first oncolytic vaccinia virus product, has successfully completed its first patient dosing at the lead clinical site, Fudan University Shanghai Cancer Center, with the subject in good condition.

The Principal Investigator (PI) of the hV01 Phase I study, Professor Jian Zhang, serves as Director of the Phase I Clinical Research Ward at Fudan University Shanghai Cancer Center, a doctoral graduate in oncology and recipient of Shanghai’s "Medical New Star" Outstanding Young Talent award. Prof. Zhang’s team has long been engaged in first-in-human (FIH) studies of innovative therapeutics and has extensive experience in this field.

hV01 is a next-generation oncolytic vaccinia virus independently developed by ConVerd’s core team, with full intellectual property rights. As the inaugural project under ConVerd’s "Systemic Tumor Immunotherapy" technology platform, hV01 is engineered with a double-gene knockout backbone virus carrying the immunomodulatory factor IL-21, which activates innate and adaptive immune responses, and serves as a marker for follicular helper T cells, bridging humoral and cellular immunity, enabling potential treatment for multiple solid tumors. The project is protected by a comprehensive global IP portfolio, covering composition, applications, manufacturing processes, and more, positioning it as a leader in its niche field.

Dr. Huiqun Xia, Chief Medical Officer of ConVerd, stated: "Guided by our Systemic Tumor Immunotherapy theory, the multi-virus technology platform developed over a decade of R&D has opened new avenues for clinical application and development. The hV01 program has garnered great anticipation and firm confidence from both the investigators and our research team. The successful first dosing of hV01 marks a milestone, and we hold expectations for its positive clinical outcomes."